1887
  1. Home
  2. Eurosurveillance
  3. Volume 30, Issue 17, 01/May/2025
  4. Article
Surveillance Open Access
Like 0
Download

Abstract

Background

, spp. and are included in the mandatory surveillance of bloodstream infections (BSI) in England.

Aim

We aimed to investigate the epidemiology of these BSIs in England April 2017–March 2022.

Methods

We extracted data on , spp. and BSI, categorised BSIs as healthcare-associated (HA) or community-associated (CA) and linked to antimicrobial susceptibility and mortality data. We used multivariable logistic regression models to assess predictors of mortality.

Results

The incidence rate of BSI was 71.8 per 100,000 population (95% confidence interval (CI): 71.5–72.1), spp. 19.1 (95% CI: 18.9–19.3) and 7.6 (95% CI: 7.5–7.7). Most (65,467/104,957) BSI episodes were CA. Case-fatality rate was 14.8% (95% CI: 14.6–14.9) in , 20.0% (95% CI: 19.6–20.3) in spp. and 25.8% (95% CI: 25.2–26.4) in BSI. Urinary tract infection (UTI) was the most reported primary infection for (56,961/100,834), spp. (9,098/22,827) and (3,204/8,484) BSI. Insertion or manipulation of urinary catheters was reported for 26.4% (16,136/61,043) of , 41.6% (4,470 /10,734) of spp. and 49.0% (2,127/4,341) of BSI. The adjusted odds ratio (OR) of death among hospital-onset HA-BSI compared to CA-BSI was 2.0 (95% CI: 1.9–2.2) for , 2.1 (95% CI: 2.0–2.3) for spp. and 1.7 (95% CI: 1.5–2.0) for .

Conclusions

Appropriate management of UTIs and urinary catheterisation is essential for reduction of these BSIs.

© Creative Commons License
This work is licensed under a Creative Commons Attribution 4.0 International License.
Loading

Article metrics loading...

/content/10.2807/1560-7917.ES.2025.30.17.2400430
2025-05-01
2025-05-02
/content/10.2807/1560-7917.ES.2025.30.17.2400430
Loading
Loading full text...

Full text loading...

/deliver/fulltext/eurosurveillance/30/17/eurosurv-30-17-2.html?itemId=/content/10.2807/1560-7917.ES.2025.30.17.2400430&mimeType=html&fmt=ahah

References

  1. United Kingdom Health Security Agency (UKHSA). English surveillance programme for antimicrobial utilisation and resistance (ESPAUR) report 2022 to 2023. London: UKHSA; Nov 2023. Available from: https://www.gov.uk/government/publications/english-surveillance-programme-antimicrobial-utilisation-and-resistance-espaur-report
  2. Perween N, Prakash SK, Siddiqui O. Multi drug resistant Klebsiella isolates in burn patients: a comparative study. J Clin Diagn Res. 2015;9(9):DC14-6. PMID: 26500905 
  3. Decraene V, Ghebrehewet S, Dardamissis E, Huyton R, Mortimer K, Wilkinson D, et al. An outbreak of multidrug-resistant Pseudomonas aeruginosa in a burns service in the North of England: challenges of infection prevention and control in a complex setting. J Hosp Infect. 2018;100(4):e239-45.  https://doi.org/10.1016/j.jhin.2018.07.012  PMID: 30012376 
  4. Tian L, Tan R, Chen Y, Sun J, Liu J, Qu H, et al. Epidemiology of Klebsiella pneumoniae bloodstream infections in a teaching hospital: factors related to the carbapenem resistance and patient mortality. Antimicrob Resist Infect Control. 2016;5(1):48.  https://doi.org/10.1186/s13756-016-0145-0  PMID: 27891222 
  5. Naylor NR, Pouwels KB, Hope R, Green N, Henderson KL, Knight GM, et al. The health and cost burden of antibiotic resistant and susceptible Escherichia coli bacteraemia in the English hospital setting: A national retrospective cohort study. PLoS One. 2019;14(9):e0221944.  https://doi.org/10.1371/journal.pone.0221944  PMID: 31504046 
  6. Shrestha P, Cooper BS, Coast J, Oppong R, Do Thi Thuy N, Phodha T, et al. Enumerating the economic cost of antimicrobial resistance per antibiotic consumed to inform the evaluation of interventions affecting their use. Antimicrob Resist Infect Control. 2018;7(1):98.  https://doi.org/10.1186/s13756-018-0384-3  PMID: 30116525 
  7. Cassini A, Högberg LD, Plachouras D, Quattrocchi A, Hoxha A, Simonsen GS, et al. Attributable deaths and disability-adjusted life-years caused by infections with antibiotic-resistant bacteria in the EU and the European Economic Area in 2015: a population-level modelling analysis. Lancet Infect Dis. 2019;19(1):56-66.  https://doi.org/10.1016/S1473-3099(18)30605-4  PMID: 30409683 
  8. Her Majesty’s Government (HM Government). Tackling antimicrobial resistance 2019 to 2024: the UK’s 5-year national action plan. London: HM Government; 24 Jan 2019. Available from: https://assets.publishing.service.gov.uk/government/uploads/system/uploads/attachment_data/file/784894/UK_AMR_5_year_national_action_plan.pdf
  9. Bou-Antoun S, Davies J, Guy R, Johnson AP, Sheridan EA, Hope RJ. Descriptive epidemiology of Escherichia coli bacteraemia in England, April 2012 to March 2014. Euro Surveill. 2016;21(35):30329.  https://doi.org/10.2807/1560-7917.ES.2016.21.35.30329  PMID: 27608263 
  10. Abernethy J, Guy R, Sheridan EA, Hopkins S, Kiernan M, Wilcox MH, et al. Epidemiology of Escherichia coli bacteraemia in England: results of an enhanced sentinel surveillance programme. J Hosp Infect. 2017;95(4):365-75.  https://doi.org/10.1016/j.jhin.2016.12.008  PMID: 28190700 
  11. United Kingdom Health Security Agency (UKHSA). Mandatory enhanced MRSA, MSSA and Gram-negative bacteraemia, and Clostridioides difficile infection surveillance Protocol version 4.4. London: UKHSA; May 2020. Available from: https://hcaidcs.phe.org.uk/ContentManagement/LinksAndAnnouncements/HCAIDCS_Mandatory_Surveillance_Protocol_v4.4.pdf
  12. Office for National Statistics (ONS). Estimates of the population for the UK, England and Wales, Scotland and Northern Ireland. Newport: ONS; 8 Oct 2024. Available from: https://www.ons.gov.uk/peoplepopulationandcommunity/populationandmigration/populationestimates/datasets/populationestimatesforukenglandandwalesscotlandandnorthernireland
  13. National Health Service England (NHS England). Bed availability and occupancy data –day only. London: NHS England; 2022. Available from: https://www.england.nhs.uk/statistics/statistical-work-areas/bed-availability-and-occupancy/bed-data-day-only/
  14. The European Committee on Antimicrobial Susceptibility Testing (EUCAST). Definitions of S, I and R. [Accessed: 24 Feb 2024]. Available from: https://www.eucast.org/newsiandr
  15. Wickham H, Averick M, Bryan J, Chang W, McGowan LD, François R, et al. Welcome to the Tidyverse. J Open Source Softw. 2019;4(43):1686.  https://doi.org/10.21105/joss.01686 
  16. Fox J, Weisberg S. An R Companion to Applied Regression, Third edition. Thousand Oaks: Sage Publications, 2019.
  17. United Kingdom Health Security Agency (UKHSA). Mandatory healthcare associated infection surveillance: data quality statement for April 2019 to March 2020. London; Jun 2022. Available from: https://www.gov.uk/government/publications/mandatory-healthcare-associated-infection-hcai-surveillance-data-quality-statement
  18. The National Health Service England (NHS England). Hospital Admitted Patient Care Activity, 2022-23. London: NHS England; 21 Sep 2023. Available from: https://digital.nhs.uk/data-and-information/publications/statistical/hospital-admitted-patient-care-activity/2022-23
  19. Sloot R, Nsonwu O, Chudasama D, Rooney G, Pearson C, Choi H, et al. Rising rates of hospital-onset Klebsiella spp. and Pseudomonas aeruginosa bacteraemia in NHS acute trusts in England: a review of national surveillance data, August 2020-February 2021. J Hosp Infect. 2022;119:175-81.  https://doi.org/10.1016/j.jhin.2021.08.027  PMID: 34547320 
  20. United Kingdom Health Security Agency (UKHSA). Annual epidemiological commentary: Gram-negative, MRSA, MSSA bacteraemia and C. difficile infections, up to and including financial year 2022 to 2023. London; 26 Sep 2024. Available from: https://www.gov.uk/government/statistics/mrsa-mssa-and-e-coli-bacteraemia-and-c-difficile-infection-annual-epidemiological-commentary
  21. Livermore DM, Hope R, Brick G, Lillie M, Reynolds R, BSAC Working Parties on Resistance Surveillance. Non-susceptibility trends among Pseudomonas aeruginosa and other non-fermentative Gram-negative bacteria from bacteraemias in the UK and Ireland, 2001-06. J Antimicrob Chemother. 2008;62(Suppl 2):ii55-63.  https://doi.org/10.1093/jac/dkn352  PMID: 18819980 
  22. Livermore DM, Hope R, Brick G, Lillie M, Reynolds R, BSAC Working Parties on Resistance Surveillance. Non-susceptibility trends among Enterobacteriaceae from bacteraemias in the UK and Ireland, 2001-06. J Antimicrob Chemother. 2008;62(Suppl 2):ii41-54.  https://doi.org/10.1093/jac/dkn351  PMID: 18819979 
  23. Gómez-Zorrilla S, Becerra-Aparicio F, López Montesinos I, Ruiz de Gopegui E, Grau I, Pintado V, et al. A large multicenter prospective study of community-onset healthcare associated bacteremic urinary tract infections in the era of multidrug resistance: even worse than hospital acquired infections? Infect Dis Ther. 2021;10(4):2677-99.  https://doi.org/10.1007/s40121-021-00537-0  PMID: 34626347 
  24. Shackley DC, Whytock C, Parry G, Clarke L, Vincent C, Harrison A, et al. Variation in the prevalence of urinary catheters: a profile of National Health Service patients in England. BMJ Open. 2017;7(6):e013842.  https://doi.org/10.1136/bmjopen-2016-013842  PMID: 28645950 
  25. Neidhöfer C, Sib E, Neuenhoff M, Schwengers O, Dummin T, Buechler C, et al. Hospital sanitary facilities on wards with high antibiotic exposure play an important role in maintaining a reservoir of resistant pathogens, even over many years. Antimicrob Resist Infect Control. 2023;12(1):33.  https://doi.org/10.1186/s13756-023-01236-w  PMID: 37061726 
  26. Laxminarayan R, Klugman KP. Communicating trends in resistance using a drug resistance index. BMJ Open. 2011;1(2):e000135-000135.  https://doi.org/10.1136/bmjopen-2011-000135  PMID: 22102636 
  27. Ohnuma T, Chihara S, Costin B, Treggiari MM, Bartz RR, Raghunathan K, et al. Association of appropriate empirical antimicrobial therapy with in-hospital mortality in patients with bloodstream infections in the US. JAMA Netw Open. 2023;6(1):e2249353.  https://doi.org/10.1001/jamanetworkopen.2022.49353  PMID: 36598788 
  28. Kadri SS, Lai YL, Warner S, Strich JR, Babiker A, Ricotta EE, et al. Inappropriate empirical antibiotic therapy for bloodstream infections based on discordant in-vitro susceptibilities: a retrospective cohort analysis of prevalence, predictors, and mortality risk in US hospitals. Lancet Infect Dis. 2021;21(2):241-51.  https://doi.org/10.1016/S1473-3099(20)30477-1  PMID: 32916100 
  29. His Majesty’s Government (HM Government). Confronting antimicrobial resistance 2024 to 2029. London: HM Government; 2024. Available from: https://assets.publishing.service.gov.uk/media/664394d9993111924d9d3465/confronting-antimicrobial-resistance-2024-to-2029.pdf
Incidence, case-fatality rates and risk factors of bloodstream infections caused by Escherichia coli, Klebsiella species and Pseudomonas aeruginosa, England, April 2017 to March 2022
<p class="citation"> <span>Citation style for this article:</span> <span class="meta-value authors"> <a href="/search?value1=Olisaeloka+Nsonwu&option1=author&noRedirect=true" class="nonDisambigAuthorLink">Nsonwu Olisaeloka</a>, <a href="/search?value1=Simon+Thelwall&option1=author&noRedirect=true" class="nonDisambigAuthorLink">Thelwall Simon</a>, <a href="/search?value1=Sarah+Gerver&option1=author&noRedirect=true" class="nonDisambigAuthorLink">Gerver Sarah</a>, <a href="/search?value1=Rebecca+L+Guy&option1=author&noRedirect=true" class="nonDisambigAuthorLink">Guy Rebecca L</a>, <a href="/search?value1=Dimple+Chudasama&option1=author&noRedirect=true" class="nonDisambigAuthorLink">Chudasama Dimple</a>, <a href="/search?value1=Russell+Hope&option1=author&noRedirect=true" class="nonDisambigAuthorLink">Hope Russell</a></span>. Incidence, case-fatality rates and risk factors of bloodstream infections caused by Escherichia coli, Klebsiella species and Pseudomonas aeruginosa, England, April 2017 to March 2022. <a href="/content/ecdc">Euro Surveill.</a> 2025;30(17):pii=2400430. <a href="https://doi.org/10.2807/1560-7917.ES.2025.30.17.2400430" title="doi link" target="_blank">https://doi.org/10.2807/1560-7917.ES.2025.30.17.2400430</a> <span class="ES_Article_citation"> <span class="generated">Received</span>: 03 Jul 2024;&nbsp;&nbsp; <span class="generated">Accepted</span>: 18 Nov 2024 </span> </p>
/content/10.2807/1560-7917.ES.2025.30.17.2400430
/content/10.2807/1560-7917.ES.2025.30.17.2400430
Loading

Data & Media loading...

Supplementary data

Submit comment
Close
Comment moderation successfully completed
This is a required field
Please enter a valid email address
Approval was a Success
Invalid data
An Error Occurred
Approval was partially successful, following selected items could not be processed due to error